The global pulmonary drug delivery system market is expected to grow from USD 30.77 billion in 2024 to USD 38.53 billion by 2029, growing at a CAGR of 4.6% from 2024 to 2029.
For instance, many changes have been made in dry powder inhalers and their usage has become way more accessible than older dry powder inhalers. Respiratory diseases such as chronic obstructive pulmonary disease and lung cancer are increasing rapidly. Asthma is nowadays very common in kids below the age of 14 years. According to the World Health Organization, lung cancer is leading worldwide in men’s deaths caused by cancer. As a result, the demand for pulmonary drug delivery systems is increasing and the trend is likely to continue during the forecast period.
The growing aging population worldwide who are more susceptible to respiratory conditions, increasing demand for targeted and efficient drug delivery to the lungs, rising preference for non-invasive and patient-friendly treatment methods and advancements in inhalation device technology enhancing drug delivery accuracy propel the pulmonary drug delivery system market growth. The emergence of biologics and personalized medicine that drive inhalation therapy, the development of innovative dry powder and metered-dose inhalers, regulatory support for pulmonary drug delivery system approvals and growing research activities on novel inhalable formulations and therapies fuel the market’s growth rate.
The introduction of smart inhalers and digital health solutions for monitoring, rising focus on reducing systemic side effects with localized lung delivery, increasing air pollution levels, rising demand for home-based respiratory treatments and growing awareness of early respiratory disease diagnosis and management show a favorable impact on the market growth.
Stringent regulations for device approval and drug delivery systems, technical challenges and high costs associated with advanced delivery devices primarily hamper the market growth. The competition from other drug delivery methods such as oral and injectable and potential adverse effects associated with inhalation therapies further impedes market growth.
The demand for pulmonary drug delivery systems has increased tremendously during the COVID-19 pandemic. Various diseases like chronic obstructive pulmonary disease and asthma are associated with COVID-19 as the after-effect of the infection. So, as the widespread pandemic worldwide took place simultaneously, the demand for pulmonary drug delivery systems has grown significantly. During the outbreak of the COVID-19 virus, the number of deaths due to respiratory diseases has also grown notably. The clinical research and the involvement of technological advancements to manufacture advanced pulmonary truck delivery systems rapidly increased. This has ultimately resulted in massive investments in pulmonary drug delivery systems. Likewise, the COVID-19 pandemic has favored the pulmonary drug delivery system market.
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2024 to 2029 |
|
Base Year |
2024 |
|
Forecast Period |
2024 to 2029 |
|
Segments Covered |
By Application, Product type and region. |
|
Various Analyses Covered |
|
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Merck & Co., Inc., Novartis AG, GSK plc, Omron Healthcare Inc. and AstraZeneca are some of the major companies in the global pulmonary drug delivery system market. |
Based on product type, the dry powder inhalers segment is anticipated to account for the leading share of the pulmonary drug delivery system market during the forecast period. Dry Powder Inhalers (DPI) are more effective as they help reach medicine to the lungs easily by producing smaller particles. They are also a pocket-friendly option compared to other available options. Dry powder inhalers have reduced reliance on patient's inhalation technique, which is one of the major factors driving the segmental growth. The elimination of propellants that make them environmentally friendly and rapid adoption in managing obstructive lung diseases further contribute to the growth of the dry powder inhalers segment in the global market.
The metered dose inhalers segment is predicted to occupy the second leading share of the global pulmonary drug delivery system market during the forecast period. The convenience, portability and the ability of precise dosing of metered dose inhalers drive the segmental growth. The availability of various drug formulations and combinations and the wide acceptance of metered dose inhalers in outpatient settings and home care further fuel the growth rate of the MDI segment in the global market.
The nebulizers segment is predicted to capture a substantial share of the global pulmonary drug delivery system market during the forecast period.
Based on application, the asthma se gment is expected to account for the leading share of the global pulmonary drug delivery system market during the forecast period. As per a report published by the World Health Organization, asthma is one of the most common chronic diseases worldwide with more than 260,000,000 patients currently suffering. The pulmonary drug delivery system is considered an effective method of medication in asthma patients to reach up to the lungs.
The cystic fibrosis segment holds a considerable share of the global pulmonary drug delivery system market during the forecast period. In cystic fibrosis, a thick layer of mucus covers the internal lining of the lungs and the esophagus/windpipe, making breathing difficult. It is a genetic disorder and is not as common as other pulmonary diseases. As the medications directly reach the lungs of the patients using the pulmonary drug delivery system, it helps improve the overall condition and the breathing problem.
North America is predicted to account for the major share of the global market during the forecast period. The increasing number of patients suffering from respiratory disorders like asthma, COPD, and cystic fibrosis is one of the major factors driving the growth of the North American market. Factors such as the presence of advanced healthcare infrastructure, growing prevalence of respiratory diseases and increasing number of research and development activities in drug delivery technologies further fuel the growth rate of the North American market. The U.S. is estimated to account for the leading share of the North American market in the coming years. Favorable reimbursement policies for respiratory therapies, growing demand for home-based treatments and patient convenience and an increasing number of initiatives from the government of the U.S. promoting respiratory health awareness fuel the growth rate of the U.S. market.
Europe accounted for a substantial share of the worldwide market in 2022 and is expected to showcase a prominent CAGR during the forecast period owing to the availability of established healthcare systems and research capabilities. High smoking prevalence and growing incidence of COPD across Europe further fuel the growth rate of the European market. COPD is one of the leading causes of morbidity and mortality in Europe.
The Asia Pacific region is the most lucrative regional market for pulmonary drug delivery systems and is estimated to witness the fastest CAGR during the forecast period. Factors such as rapid urbanization, lifestyle changes, high levels of air pollution, growing healthcare investments, rising emphasis on disease prevention, growing aging population and rapid adoption of innovative healthcare technologies majorly drive the APAC market growth.
Latin America and, the Middle East & Africa are anticipated to account for a considerable share of the worldwide market during the forecast period.
Merck & Co., Inc., Novartis AG, GSK plc, Omron Healthcare Inc. and AstraZeneca are some of the major companies in the global pulmonary drug delivery system market.
Nebulizers
Dry Powder Inhalers
Frequently Asked Questions
The North American pulmonary drug delivery market is expected to grow significantly and hold the largest revenue share during the forecast period.
Merck & Co., Inc.,Novartis AG,GSK plc,Omron Healthcare Inc,AstraZeneca are some of the key market players.
The global pulmonary drug delivery market is expected to grow at a CAGR of 4.6% during the forecast period.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region